EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 39 / No 12 (Décembre 2023) Med Sci (Paris), 39 12 (2023) 958-966 References
Open Access
Issue
Med Sci (Paris)
Volume 39, Number 12, Décembre 2023
Page(s) 958 - 966
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2023177
Published online 18 December 2023
  1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014 ; 2 : e106–e116. [CrossRef] [PubMed] [Google Scholar]
  2. Garcia-Garcia J, Usategui-Martin R, Sanabria MR, et al. Pathophysiology of Age-Related Macular Degeneration: Implications for Treatment. Ophthalmic Res 2022; 65 : 615–36. [CrossRef] [PubMed] [Google Scholar]
  3. Spooner K, Mhlanga C, Hong T, et al. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol 2018 ; 12 : 2483–2491. [CrossRef] [Google Scholar]
  4. Fonteh CN, Mathias MT, Mandava N, et al. Mental health and visual acuity in patients with age-related macular degeneration. BMC Ophthalmol 2022; 22 : 391. [CrossRef] [PubMed] [Google Scholar]
  5. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006 ; 58 : 353–363. [PubMed] [Google Scholar]
  6. Roubeix C, Sahel JA, Guillonneau X, et al. Sur les origines inflammatoires de la DMLA. Med Sci (Paris) 2020; 36 : 886–92. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol 2001 ; 119 : 1417–1436. [CrossRef] [PubMed] [Google Scholar]
  8. Davis MD, Gangnon RE, Lee L-Y, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005 ; 123 : 1484–1498. [CrossRef] [PubMed] [Google Scholar]
  9. Bakri SJ, Bektas M, Sharp D, et al. Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system. J Manag Care Spec Pharm 2023; 29 : S2–S11. [PubMed] [Google Scholar]
  10. Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 2023; 402 : 1449–58. [CrossRef] [PubMed] [Google Scholar]
  11. Leveziel N, Soubrane G, Souied EH. Anti-VEGF : applications pratiques en ophtalmologie. Med Sci (Paris) 2009 ; 25 : 1105–1107. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Schultz NM, Bhardwaj S, Barclay C, et al. Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review. Clin Ther 2021; 43 : 1792–818. [CrossRef] [PubMed] [Google Scholar]
  13. Doshi RR, Bakri SJ, Fung AE. Intravitreal Injection Technique. Semin Ophthalmol 2011 ; 26 : 104–113. [CrossRef] [PubMed] [Google Scholar]
  14. Pina Marín B, Gajate Paniagua NM, Gómez-Baldó L, et al. Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: Results of the AMD-MANAGE study. Eur J Ophthalmol 2022; 32 : 385–94. [CrossRef] [PubMed] [Google Scholar]
  15. Hollaus M, Bühl W, Schmidt-Erfurth U, et al. The Challenges of Treating Neovascular Age-Related Macular Degeneration. Klin Monbl Augenheilkd 2022; 239 : 1033–42. [CrossRef] [PubMed] [Google Scholar]
  16. Korobelnik J-F, Delcourt C, Creuzot-Garcher C, et al. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. J Med Econom 2021; 24 : 1087–97. [CrossRef] [PubMed] [Google Scholar]
  17. Boyle J, Vukicevic M, Koklanis K, et al. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychology, Health & Medicine 2018 ; 23 : 127–140. [CrossRef] [PubMed] [Google Scholar]
  18. Li E, Donati S, Lindsley KB, et al. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2020; 5 : CD012208. [PubMed] [Google Scholar]
  19. del Amo EM, Rimpelä A-K, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res 2017 ; 57 : 134–185. [CrossRef] [PubMed] [Google Scholar]
  20. Singh M, Bharadwaj S, Lee KE, et al. Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery. J Control Release 2020; 328 : 895–916. [CrossRef] [PubMed] [Google Scholar]
  21. Herrera-Barrera M, Ryals RC, Gautam M, et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv 2023; 9 : eadd4623. [CrossRef] [PubMed] [Google Scholar]
  22. Xu J, Xue Y, Hu G, et al. A comprehensive review on contact lens for ophthalmic drug delivery. J Control Release 2018 ; 281 : 97–118. [CrossRef] [PubMed] [Google Scholar]
  23. National Institutes of Health Clinical Center (CC). A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration. clinicaltrials.gov, 2020. https://clinicaltrials.gov/ct2/show/NCT00306488. [Google Scholar]
  24. Alcon Research. The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). clinicaltrials.gov, 2014. https://clinicaltrials.gov/ct2/show/NCT00890097. [Google Scholar]
  25. MacuCLEAR, Inc., Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 1.0% BID in the Treatment of Non-exudative Age-Related Macular Degeneration. clinicaltrials.gov, 2014. https://clinicaltrials.gov/ct2/show/study/NCT02127463. [Google Scholar]
  26. Vogl W-D, Riedl S, Mai J, et al. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning. Ophthalmol Retina 2023; 7 : 4–13. [CrossRef] [PubMed] [Google Scholar]
  27. CoMentis. A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients With Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab). clinicaltrials.gov, 2010. https://clinicaltrials.gov/ct2/show/study/NCT00607750. [Google Scholar]
  28. GlaxoSmithKline. MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration. clinicaltrials.gov, 2017. https://clinicaltrials.gov/ct2/show/study/NCT01134055. [Google Scholar]
  29. Bayer. A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration. clinicaltrials.gov, 2016. https://clinicaltrials.gov/ct2/show/NCT02222207. [Google Scholar]
  30. Poor SH, Weissgerber G, Adams CM, et al. A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol 2022; 239 : 180–9. [CrossRef] [PubMed] [Google Scholar]
  31. Ohr Pharmaceutical Inc. OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD). clinicaltrials.gov, 2017. https://clinicaltrials.gov/ct2/show/study/NCT02727881. [Google Scholar]
  32. PanOptica, Inc. A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants With Neovascular Age-Related Macular Degeneration (AMD). clinicaltrials.gov, 2019. https://clinicaltrials.gov/ct2/show/NCT03479372. [Google Scholar]
  33. Chaney P. PAN-90806: once-daily topical anti-VEGF eye drop for wet AMD and other neovascular eye disease. Ophthalmology Innovation Summit, San Francisco 2019. https://www.panopticapharma.com/wp-content/uploads/2019/10/PAN-90806-Data-at-OIS@AAO.pdf. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.